Custom service

Peptide-siRNA Conjugation

Couple peptides to sirna strands for targeted knockdown studies

Turnaround: 4–6 weeksTypical scale: 0.1–50 mg conjugate per batchChemistry options: 3'-C6-maleimide oligonucleotide conjugation; GalNAc and CPP targeting ligands; RNase-free handling workflow

Peptide-siRNA Conjugation supports programmes that couple peptides to siRNA strands for targeted knockdown studies. In a typical engagement we plan the 3'-C6-maleimide oligonucleotide conjugation route first, confirm compatibility with GalNAc and CPP targeting ligands, and release purified siRNA conjugate under RNase-free QC on a 4–6 weeks schedule.

Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep 3'-C6-maleimide oligonucleotide conjugation as the primary option and hold GalNAc and CPP targeting ligands in reserve, so that scale-up never depends on an unproven step.

GalNAc-driven hepatocyte delivery studies

Cell-targeted knockdown screening

Material intended for systemic in-vivo dosing

Conjugates whose payload cannot tolerate aqueous coupling conditions

Every conjugation batch is documented from vial to vial: carrier lot, payload lot, reagent lots, reaction conditions and purification chromatograms. The release package contains the loading ratio measured by an orthogonal method (UV, ICP-MS or amino-acid analysis), identity by mass spectrometry where the conjugate permits it, and residual-free-payload data.

Service Highlights

  • 3'-C6-maleimide oligonucleotide conjugation as the default route, with GalNAc and CPP targeting ligands held as a proven fallback
  • RNase-free handling workflow worked into the design where the application requires it
  • Carrier and payload compatibility screened in a small feasibility batch before full material is committed
  • Analytical confirmation of every intermediate before the final release
  • Unreacted payload driven below the detection limit of the release assay before purification is closed
  • Purified siRNA conjugate under RNase-free QC delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Scope & design

    We review the payload, the carrier and the intended assay or study, and propose between 3'-C6-maleimide oligonucleotide conjugation and GalNAc and CPP targeting ligands as candidate routes.

  2. Feasibility screen

    A milligram-scale screen compares loading, residual payload and activity across the candidate conditions.

  3. Production conjugation

    The selected condition is executed at project scale with in-process sampling at fixed time points.

  4. Purification

    Size-exclusion, dialysis or magnetic separation removes free payload and by-products.

  5. Characterization & release

    Identity, loading ratio and functional activity are measured against the agreed specification.

  6. Documentation & hand-off

    Purified siRNA conjugate under RNase-free QC is packaged with the full batch record, released for shipment after QC sign-off.

Specifications & timeline

Turnaround
4–6 weeks
Typical scale
0.1–50 mg conjugate per batch
Chemistry options
3'-C6-maleimide oligonucleotide conjugation; GalNAc and CPP targeting ligands; RNase-free handling workflow
Deliverable
Purified siRNA conjugate under RNase-free QC
QC package
HPLC/SEC trace, MALDI-TOF or ESI-MS, UV/Vis or ICP-MS loading ratio
Shipping
Blue ice or dry ice as the payload requires, with a cold-chain manifest

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.